Medical Access and Reimbursement in Norway

Currently classified as a strictly controlled substance under Norway's narcotics scheduling and national drug laws, with no authorized medical use outside of approved clinical research. National authorities (Statens legemiddelverk / the Directorate for Medical Products and related guidance) treat psilocybin-containing fungi and preparations as prohibited; import, possession and distribution are criminalized except where explicitly authorized for regulated research or named-patient/compassionate-use pathways. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is treated as an illicit substance for possession, import and supply under Norwegian law; any therapeutic use would require formal approval within clinical trials or regulatory exceptional pathways. #

Esketamine (intranasal Spravato®) is a licensed medicinal entity internationally for treatment‑resistant depression, but in the Norwegian reimbursement/implementation process it has not been adopted into national public reimbursement — Norwegian decision bodies have distinguished between branded esketamine and generic/off‑label ketamine approaches. Norwegian national deliberations have resulted in public specialist services choosing to adopt off‑label racemic ketamine rather than extend reimbursement to the licensed esketamine product; press reporting and policy commentary indicate that Beslutningsforum's August 25, 2025 decisions approved off‑label ketamine for treatment‑resistant depression while declining to incorporate Spravato into the public reimbursement pathway. # #

Regulatory and payer context: market authorization status for esketamine is separate from Norway's decisions about public reimbursement and implementation in specialist services; in Norway decisions about public adoption and reimbursement are taken by Beslutningsforum (and associated HTA/‘Nye metoder’ processes), which in 2025 elected not to reimburse Spravato while enabling an alternative ketamine pathway. #

Ketamine (racemic IV ketamine) is available for standard medical uses (anesthesia and analgesia) and — following national review processes in 2025 — has been authorized for public use and reimbursement off‑label as a treatment for treatment‑resistant depression within Norway's specialist health services. The decision by Beslutningsforum on 25 August 2025 explicitly permits intravenous ketamine for treatment‑resistant depression provided it is delivered within hospitals or district psychiatric centres (DPS), patients are informed of the off‑label status, and treated patients are followed within registries or clinical studies; the decision will be re‑evaluated by the end of 2028. This pathway therefore creates publicly funded access (no out‑of‑pocket requirement for patients treated within the public specialist services) but under constrained conditions. # #

Regulatory bodies and payer roles: the Norwegian implementation involved multiple authorities — the Directorate for Medical Products (DMP / Statens legemiddelverk) and the regional health trusts working through the Nye Metoder / Beslutningsforum process that governs adoption and reimbursement in specialist care. The medical indication specified by Beslutningsforum is treatment‑resistant depression (patients who have not responded to appropriate prior treatments), and services must operate within hospital/DPS settings with registry or trial follow‑up; clinicians must obtain informed consent documenting the off‑label nature of the use. # #

Reimbursement and delivery nuance: the Beslutningsforum decision makes ketamine treatment publicly funded when provided in the specialist health service under the decision's conditions; private clinics may continue to offer off‑label ketamine (often at patient expense) but public commissioning now enables equitable access through regional health services with oversight. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and ayahuasca preparations containing DMT) is treated as prohibited for import, possession and supply except within formally authorised research or exceptional regulatory permissions. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Norway's narcotics regulations list 5‑MeO‑DMT and related tryptamine derivatives among substances regarded as illegal to import, possess or distribute outside of authorised scientific/clinical activity. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no established, authorized clinical or reimbursement pathway for ibogaine in Norway; access would be limited to approved studies or exceptional named‑patient arrangements, if granted. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (such as ayahuasca brews) are treated as illegal for importation, possession and use outside of tightly regulated research or specific legal exemptions. Religious‑use defenses are not generally recognized as statutory exceptions; access remains limited to authorised research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti preparations are controlled; importation, possession and supply are subject to criminal penalties except where explicitly authorized for research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Norway's narcotics regulation and periodic updates to the 'narkotikalisten' include many 2C‑series compounds (2C‑I, 2C‑E, 2C‑B etc.) as prohibited substances; possession, import and distribution are criminal offences absent regulatory exceptions. # #